Clinical trials: Head and Neck Cancer Metastatic
Nasopharyngeal Carcinoma
Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients
The investigators have demonstrated the crucial role of the liver-lung axis in the distant metastasis of NPC. Furthermore, the investigators have identified a potential therapeutic approach to improve outcomes in NPC patients by…
- Trial name
- NCT06442709
- Testing
- Tocilizumab Asprin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Affiliated Hospital of Nantong University
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison
Carcinoma, Squamous Cell of Head and Neck
Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients
The purpose of this study is to identify predictive and pharmacodynamic biomarkers of activity and efficacy of pre-operative Afatinib (BIBW2992) in untreated non-metastatic head and neck squamous cell carcinoma patients
- Trial name
- PREDICTOR (NCT01415674)
- Testing
- Afatinib
- Where
- 11 sites in France
- Volunteers
- 61 people
- Sponsor
- UNICANCER
Cervical Cancer, Throat Cancer
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers.
- Conditions
- Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer
- Trial name
- NCT05686226
- Testing
- E7 TCR-T cells, Aldesleukin
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Christian Hinrichs
Recurrence, Metastasis
Prognostic Value of CTC in HNSCC Patients
We hypothesized that the number of circulating tumor cells (CTCs) and molecular markers on CTCs could be a prognostic factor or predictive factor to patients with head neck cancer.
- Conditions
- Recurrence, Metastasis, Death
- Trial name
- CTCHNSCC01 (NCT01884129)
- Where
- Taiwan
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Thyroid Cancer
RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers
The purpose of this study is to find out what effects, good and/or bad, a drug called durvalumab combined with Thyrogen-stimulated RAI, has on the patient and thyroid cancer.
- Trial name
- NCT03215095
- Testing
- Durvalumab (Medi4736), Radioiodine (RAI)
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Nasopharyngeal Cancer
To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
The purpose of this study is to assess the efficacy of addition of zometa to anti-neoplastic treatment compared with anti-neoplastic treatment alone, as measured by the primary efficacy variable of SREs (Skeletal Related Events)…
- Trial name
- NCT00697619
- Testing
- Zometa (zoledronic acid)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Head and Neck Cancer
Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of docetaxel in treating patients with advanced solid…
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00002901
- Testing
- docetaxel
- Where
- 3 sites in United States
- Sponsor
- City of Hope Medical Center
Head and Neck Cancer, Skin Reactions Secondary to Radiation Therapy
Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, but may cause skin irritation and inflammation. Biafine cream may be effective in lessening side effects caused by radiation therapy.
- Trial name
- NCT00006481
- Testing
- Biafine cream, quality-of-life assessment, radiation therapy
- Where
- 260 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Head and Neck Cancer
Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer
The clinical hypothesis of this study is that the first-line treatment with the combination of panitumumab and paclitaxel will provide benefit for patients with metastatic or current Squamous Cell Carcinoma of the Head and Neck…
- Trial name
- VECTITAX (NCT01264328)
- Testing
- Panitumumab + paclitaxel
- Where
- 12 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Head and Neck Squamous Cell Carcinoma
HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy
This study is to explore the efficacy and safety of GX-188E DNA vaccination, GX-I7, and nivolumab combination therapy in HPV 16-positive and/or HPV-18 positive R/M HNSCC patients. The objective of this study is as follows.
- Trial name
- TRINITY (NCT05280457)
- Testing
- nivolumab-GX-188E-GX-I7
- Where
- South Korea
- Volunteers
- 21 people
- Sponsor
- Yonsei University
Brain Tumors, Central Nervous System Tumors
Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma
RATIONALE: Electroacupuncture may help to reduce or prevent delayed nausea and vomiting in patients treated with chemotherapy. PURPOSE: This randomized clinical trial is studying the effectiveness of electroacupuncture in…
- Conditions
- Brain Tumors, Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
- Trial name
- NCT00040911
- Testing
- electroacupuncture therapy, quality-of-life assessment
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Children's Oncology Group
Esophageal Cancer
LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma
The goal of this clinical research study is to find the highest tolerable dose of LDE225 that can be given in combination with everolimus to patients with esophageal or GEJ cancer.
- Trial name
- NCT02138929
- Testing
- Everolimus, LDE 225
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
This is a randomized, open-label, active-comparator-controlled, multi-regional, three-arm, phase 3 study comparing the efficacy and safety of ivonescimab in combination with ligufalimab to pembrolizumab and of ivonescimab alone…
- Trial name
- ILLUMINE (NCT07264075)
- Testing
- Ivonescimab 10 mg/kg, Ligufalimab, Pembrolizumab (KEYTRUDA ®)
- Where
- France
- Volunteers
- 780 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Melanoma, Non-Small Cell Lung Cancer
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
This study is a dose escalation of GR-MD-02 with the standard therapeutic dose of pembrolizumab in patients with advanced melanoma, non-small cell lung cancer, and head and neck squamous cell cancer.
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02575404
- Testing
- GR-MD-02, Pembrolizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Providence Health & Services
Head and Neck Squamous Cell Carcinoma
Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of the study is to find out if the study drugs Avelumab, Cetuximab, and Palbociclib will slow or stop your cancer from getting worse, and whether it causes side effects.
- Trial name
- NCT03498378
- Testing
- Avelumab, Palbociclib, Cetuximab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Kathryn Gold
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
A study for identification of immune determinants for response to Nivolumab in Recurrent /Metastatic HNSCC(Head and neck squamous cell carcinoma) patients.
- Trial name
- NCT04603248
- Testing
- Nivolumab
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yonsei University
Head and Neck Squamous Cell Carcinoma
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to assess the safety, pharmacokinetic and efficacy of TL117 plus paclitaxel in patients with recurrent or metastatic head and neck cancer.
- Trial name
- NCT04843098
- Testing
- TL117, Paclitaxel
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Suzhou Junde Biotechnology Co., Ltd
Locally Advanced or Metastatic Solid Tumors
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies.
- Trial name
- NCT07730021
- Testing
- ASP388B, Pembrolizumab, Carboplatin
- Where
- 4 sites in United States, Japan
- Volunteers
- 392 people
- Sponsor
- Astellas Pharma Global Development, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.